INTRODUCTION
Inhaled drugs are essential for the treatment of asthma and chronic obstructive pulmonary disease (COPD) [1, 2] , but drug delivery via the respiratory tract is more complex than oral therapy. Correct use of the inhaler is necessary to enable the medication to be effectively delivered to the lungs with maximized clinical efficacy and minimized systemic side effects [3] . Still, a significant proportion of patients makes inhaler technique errors [3] [4] [5] . Generic inhalation instructions apply to all inhalers; to exhale before the inhalation and to inhale as deeply as possible; slow through a pressurized metered dose inhaler (pMDI), and fast through a dry powder inhaler (DPI) [6] . Also, most pMDIs should be shaken before use, while the majority of DPIs should not [7] . This in vitro study evaluates the impact of potential patient mishandling errors on the performance of different inhalers.
In the Nordic countries, the majority of treatments with fixed or free combinations of inhaled corticosteroids and long-acting beta 2 -agonists are delivered by a DPI [8] . However, there are differences between DPIs, e.g. in the formulation of the drug. The fine particle dose (FPD) dependency of the inhalation air flow rate is a fundamental characteristic of DPIs. Depending on the design of the device, the properties of the dry powder formulation and the interaction between these, DPIs may have different inhalation flow rate dependency profiles. Further, the patient's inhalation volume is an important patient-related factor when selecting an inhaler. The inhalation volume needed for complete dose emission and, consequently, delivered dose (DD) from the inhaler, may vary between devices. Hence, a low inhalation volume could compromise the DD [9] .
In addition, each device has its own specific instructions on how to prepare the dose for reliable drug delivery, e.g. removing the protective cap, pushing a lever, or specific preparations such as shake or not shake the inhaler before use [7] . Differences in shelf life, time in-use [10] and storage conditions such as protection against humidity [8] should also be considered. Hence, the device should be selected based on patient's characteristics, the likelihood of success with the inhalation manoeuvres, inhalation technique and patient preference [11] .
The aim of this in vitro study was to examine the impact of inhalation flow, inhalation volume and handling errors on the performance of three commonly used budesonide/formoterol (BUD/FORM) DPIs. The FPD was measured using the Next Generation Impactor (NGI) [12, 13] operating at fixed pressure drops of 2, 4 and 6 kPa. The flow rates obtained were 45, 64 and 78 L/min, respectively, for Turbuhaler and Spiromax, and 40, 56 and 69 L/min, respectively, for Easyhaler. The NGI was equipped with a pre-separator. The volume of air drawn through the inhalers and the NGI was fixed to 4 L. The FPD is defined as the amount of active pharmaceutical ingredient (API) contained in particles\5 lm in size and the amount was calculated using interpolation between relevant stages which depend on the flow rate (stage cut-offs vary with varying flow rate). For each product and flow rate, three inhalers were tested. For each inhaler, doses 1-6 were analyzed.
METHODS

Materials
Inhalation Volume Test
Three samples from each of the inhalers were tested at 0.25-, 0.5-, 1.0-, 2.0-and 4.0-L inhalation volume. For each inhaler, doses 1-3 were wasted using a 4-L inhalation volume. Doses 4, 6, 8, 10 and 12 were tested for each of the different inhalation volumes. Doses 5, 7, 9 and 11 were wasted using 4-L inhalation volume in order to eliminate any memory effect from the previous dose.
Shaking Test
Doses 1-5, 58-62 and 116-120 were tested for the 160/4.5-lg products and doses 1-5, 28-32 and 56-60 were tested for the 320/9-lg products. The inhalation volume was 4 L [14] . Shaking of each tested device was performed manually by an experienced analyst, with five shakes (downup-down-up-down) of 3-4 s in duration, with a shake length of approximately 0.15 m. This is consistent with the shaking required for effective use of a pMDI and can be considered as representative of a likely patient error in a real-world setting. All inhalers were shaken in the same way. For each product and strength, five inhalers were tested with shaking and five inhalers without shaking. Turbuhaler and Easyhaler were shaken before loading the dose. This is in accordance with the Easyhaler patient instruction; there is no mentioning of shaking in the Turbuhaler instruction. Spiromax was shaken after the dose loading (opening of the cap) which is at odds with the patient instruction to not shake.
Delivered Dose Testing
Both the inhalation volume test and the shaking test were carried out at an airflow rate equivalent to a 4-kPa pressure drop over the inhalers, i.e. 64 L/min for both Turbuhaler and Spiromax and 56 L/min for BUD/FORM Easyhaler. The doses were collected on Respirgard II, 303EU filters. The filters were extracted with a suitable solvent (50% methanol in water) containing an internal standard (butyl 4-hydroxybenzoate) and the sample solutions were quantified by isocratic reversed-phase liquid chromatography. Both budesonide and formoterol were measured.
All tests were performed by an independent laboratory.
Statistical Analyses
For each product and for each API, the effect of inhalation volume was investigated. The results obtained at 0.25, 0.5, 1.0 and 2.0 L were compared to the results obtained at 4.0 L using a paired t test. Bonferroni's correction for multiple tests was applied [15] to declare statistical significance with an overall alpha level of 0.05 (0.05/4 = 0.0125 for each comparison).
Compliance with Ethics Guidelines
As an in vitro study, this article does not contain any new studies with human or animal subjects performed by any of the authors.
RESULTS
Flow Rate Dependency of FPD
The FPD ratio of low flow vs. medium flow was consistently about 0.8 for all inhalers and strengths, and for both APIs. Similarly, the ratio of high flow vs. medium flow was about 1.1. While the FPD results for budesonide were reasonably consistent between the inhalers and within strengths (Fig. 1) , the FPD results for formoterol were consistently higher for Turbuhaler compared to the analogues (Fig. 2) .
Effects of Inhalation Volume
For Turbuhaler, the DD was unaffected by the inhalation volume down to 1 L. For the lower volumes, the DD decreased by about 10%, which was statistically significant for 0.25 L (both strengths) and for 0.5 L (only the higher strength; Fig. 3 ). For Easyhaler, the DD was unaffected for all volumes down to 0.5 L and showed an approximate 10% decrease at 0.25 L, although not statistically significant except for the formoterol component in the lower strength (Fig. 3) . The delivered dose for Spiromax showed a significant inhalation volume dependence. At the lowest volume, 0.25 L, the budesonide and formoterol DD values for the 160/4.5-lg strength was about 50% of the value obtained at 4-L volume. There were statistically (Fig. 3) .
Effects of Shaking and No Shaking
For a Turbuhaler 160/4.5-lg/dose, there were no differences in the DD between shaking and no shaking for any of the APIs (Table 1) . For the higher strength, 320/9-lg/dose, a small decrease in DD, approximately 10% for both APIs, was observed after shaking compared to no shaking (Fig. 4a) . For Easyhaler, the DD for both APIs and for both strengths decreased by about 50% when the device was not shaken (Fig. 4a, b) . The results for Spiromax indicated that the two strengths were impacted by shaking to a different extent. The lower strength showed an approximate 20% decrease in DD for both APIs when shaken compared to not shaken (Table 1) , while for the higher-strength dose, the decrease was about 80% for both APIs when the device was shaken (Fig. 4c) .
DISCUSSION
In this in vitro study, we found that the three inhalers tested were equally flow-dependent regarding the FPD of budesonide and formoterol. The Turbuhaler and Easyhaler inhalers showed non-dependency of inhalation volume for DD, whereas Spiromax had a clinically relevant inhalation volume dependency for DD when inhaling with low inhalation volume. Further, we found that there were major differences in inhaler performance when inhaler-specific pre-inhalation instructions were not followed. The present study reports that Spiromax DD decreased by 20% and 80% for the low and the high strengths, respectively, when shaken before use, whereas Easyhaler decreased by 50% for both strengths if it was not shaken prior to use. The DD from the Turbuhaler was similar, regardless if shaken or not. devices has been extensively studied [16, 17] . For analogues to be approved in the European Union (EU), it is a prerequisite that the particle size distribution is similar to the originator product at three different flow rates: low, medium and high [18] . The EU approvals of the BUD/FORM Turbuhaler analogue products, Easyhaler and Spiromax, were based on pharmacokinetic data and by showing that the flow rate dependency of FPD was similar to the originator product [19, 20] . A previous study, comparing Turbuhaler and Easyhaler, had shown similar flow rate dependency of the devices [21] . In that study, the flow rate ranges investigated were shifted upwards, 45-75 L/min for Easyhaler and 55-93 L/min for Turbuhaler, compared to the present study. The pharmacopeia standard test condition at 4 kPa was used as the medium flow rate and the low and high flow rates, equivalent to 2 and 6 kPa, respectively, were selected in accordance with De Boer et al. [16] . The results in our study showed a similar FPD flow rate dependency between the three inhalers tested. Data regarding the impact of inhalation volume is scarce. The present study reports on an apparent inhalation volume dependency for DD for Spiromax, whereas Turbuhaler and Easyhaler showed non-dependency of inhalation volume, a difference that may have impact on clinical outcomes. Patients with COPD have significantly lower inhalation volumes, approximately 2 L, compared to healthy subjects [22] [23] [24] [25] [26] . A study by Seheult reported that the mean inspiratory vital capacity (IVC) was 2.13 L (±0.79) [23], whereas Azous et al. reported an IVC of 1.82 L (±0.88) in patients with moderate COPD (FEV 1 52% predicted normal), and 1.90 L (±0.90) after enhanced training [26] . Important to note is also the decline of the inhalation volume as the disease progresses. In severe and very severe COPD, the inhalation volume has been reported to decrease to 1.7 L (CI 1.4-2.1) and 1.3 L (CI 1.1-1.5), respectively [24] . Low inhalation volumes in patients using volume-dependent inhalers may result in the inhalation volume being too low to allow drug emission. Volume dependence may also have an impact in children and adolescents with asthma, since this population have considerably lower inhalation volumes, 1.50 L (0.6) and 2.03 L (0.81), respectively [26] .
In addition, studies have shown that one third of the patients fail to exhale and inhale deep before inhalation, leading to additional decrease of the actual inhalation volume [5] . In this context it should be noted that the delivered dose test volume described in the European Pharmacopeia, developed for quality control and registration purposes, is 4 L. Thus, a volume dependence of an inhaler would not be detected during routine quality testing [12] .
To our knowledge, the impact of shaking or not shaking the device before use has not been previously reported. The present study showed that Turbuhaler was virtually unaffected by shaking while both Easyhaler and Spiromax were severely affected when the products were either shaken (Spiromax) or not shaken (Easyhaler). There is no mentioning of shaking before use in the Turbuhaler patient information leaflet, only that it should be held upright when loading a dose. The Easyhaler patient information leaflet, however, states that the device should be shaken vigorously up and down 3-5 times before use. This is contrary to Spiromax, which should not be shaken according to the patient information leaflet. It has been shown in several studies that simultaneous use of different types of inhaler device, particularly a mixture of pMDI and DPI inhalers, is predictive of increased errors in inhalation [27, 28] . It has also been reported that up to 37% of the patients fail to shake their pMDI before inhalation [3, 29, 30] . Hence, if Spiromax is concomitantly used with a pMDI, the risk of confusion is obvious.
This study comes with several limitations, the major being that it was conducted in vitro. The impact of real-life conditions in everyday patient use were not tested, thereby excluding other potential handling errors or patient-related factors, which may have affected the results. Further, the clinical implications associated with the findings in this in vitro study have not been investigated; however, the magnitude of decrease in DD and FPD observed for some of the inhalers tested may have an impact on clinical outcomes.
High rates of incorrect inhaler technique have been reported [31] and incorrect inhaler technique is considered as a common cause of uncontrolled asthma [3, 32] . Severe exacerbations and asthma-related hospitalizations have been reported to be significantly more common among patients making C1 critical inhaler error, compared to those making no errors [5] . Even after meticulous instructions to ''mastery'' in inhaler technique, the erosion of patient compliance to inhalation instructions is fast. Already one month after initial instructions, only 60% of the patients used the inhalers correctly [33] . The Global Strategy for Asthma Management and Prevention (updated in 2016), states that up to 80% of asthma patients do not use their inhaler correctly [1] . In addition, it has been shown that exposure to a new inhaler device without training is associated with decreased asthma control [34, 35] .
The decrease in DD and FPD observed for some of the inhalers in the present study may have clinical implications in patients with low inhalation capacity or patients non-adherent to inhaler instructions.
The role of the health care providers in inhaler use is, therefore, critical, both in achieving initial correct inhaler technique and also in maintaining correct inhaler use over time.
CONCLUSIONS
While there are similarities between the tested DPIs regarding the generic inhalation maneuver needed to deliver budesonide and formoterol, there are differences in the device-specific pre-inhalation instructions. This study revealed significant differences in inhaler performance after testing at different inhalation flows and volumes, and exposure to potential pre-inhalation handling errors, which may lead to decreased drug delivery to the lungs. The choice of inhaler should be individualized, as not all inhalers are suitable for all patients. Instructions for optimal inhalation technique and specific device handling need to be in focus, both for health care professionals and for patients.
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